At DP Clinical, we are monitoring the evolving news around COVID-19 and following the best practices provided by health organizations. We want you to know that the health and well-being of our team and yours is of the utmost importance to us and is guiding our decisions during this unprecedented time. DP Clinical has implemented its business continuity procedures, and our staff is working remotely with all systems and services in place to ensure business proceeds without interruption. We are working tirelessly to help everyone stay safe while at the same time continuing to serve you.
Please know we are always available to you by email or phone.
This is a difficult time for all those directly and indirectly affected by COVID-19, and we will strive to make sure we are doing everything possible to minimize risk for our staff, vendors, sites, and particularly patients.
The DP Clinical Team
ROCKVILLE, MD – November 19, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; continues its growth with the addition of Nicholas Allen as Vice President, Business Development. In this key role, Mr. Allen will draw from his 20 years of sales, marketing, and business development experience in the drug development arena working with large multinational pharmaceutical companies to small, virtual organizations to grow DP Clinical’s market presence and strategic placement within the CRO community.
For the last 9 years, Mr. Allen has been responsible for new business needs in the US and has also focused on Asia-Pacific customers, particularly Japan. Prior to joining DP Clinical, Mr. Allen was the Director of Business Development at a large CRO and was instrumental in establishing their regional office in Japan, an integral part of their corporate strategy for growth in Asia-Pacific. During his career in the industry he as worked in project management as well as in marketing. Nick received his BA Degree in English Literature from the University of Sheffield, Sheffield UK.
“Nick’s wealth of knowledge in business development and experience in clinical research will clearly be an asset to our team,” stated Devinder Poonian, President and CEO. “He is a proven strategic thinker with a pragmatic approach to resolve challenges and implement ideas – these skills are critical to DP Clinical’s growth, particularly in the business development area, and we are excited to have him join our team,” she continued.
DP Clinical again sponsored the third NASCIC Annual Meeting held in Cleveland, OH. This meeting is instrumental in bringing together members for collaboration and interaction. A key objective of this meeting was to discuss strategies for engaging people with spinal cord injuries in research and to identify opportunities to strengthen relationships between members and the research community. Michele Towle, Assistant Director, SCI Program, at DP Clinical, was a panelist on the Partner Panel discussion designed to share information on how the SCI community and researchers can work together – patient-centered research, patient engagement, advocacy efforts, resources needed to improve communication were topics discussed.
NASCIC’s mission is to bring about unified achievements in research, care, and policy by fostering collaborative efforts across the spinal cord injury community.
ROCKVILLE, MD – September 18, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; congratulates ADMA Biologics’ on the approval of ASCENIV™ (immune globulin intravenous, human – slra 10% liquid). DP Clinical provided a full complement of CRO services for ADMA Biologics program (formerly referred to as RI-002) indicated for the treatment of Primary Humoral Immunodeficiency Disease (PIDD) in adults and adolescents. Click here to read more.
REDWOOD CITY, Calif., Aug. 12, 2019 /PRNewswire/ — DP Clinical, Inc. and Comprehend Systems, Inc. are joining forces to transition the Rockville, Maryland-based CRO from spreadsheets and EDC reports to a system that aligns study teams with visual data analytics, automated KRI monitoring with alerts, and fully-auditable task management workflow. Click here to read more.
ROCKVILLE, MD – July 15, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; today announced that July 1st, 2019, marked the company’s 25-year anniversary providing CRO services to pharma, biotech, and medical device companies. Click here to read more.
DP Clinical’s CEO, Devinder Poonian, was interviewed by Applied Clinical Trials for their June issue discussing a CRO’s perspective on the evolution of clinical trials. DP Clinical has been in business for more than 24 years, and Ms. Poonian shares her observations on industry changes, CRO size, and spinal cord injury trials. The article is available at http://www.appliedclinicaltrialsonline.com/clinical-trial-evolution-cro-s-perspective
The North American Spinal Cord Injury Consortium (NASCIC) has the mission to bring about unified achievements in research, care, and policy by fostering collaborative efforts across the spinal cord injury community. DP Clinical is an inaugural member of this important organization that brings together like-minded organizations, individuals, and groups to improve research, care, and policies impacting people living with spinal cord injury, families, and the community. Working collaboratively, the organization is structured to effectively bring out collective change through approved projects.
Michele Towle, from DP Clinical, is the Chair of the American Spinal Cord Injury Association’s (ASIA) Clinical Trial Training Program Committee for International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Training. This new program will allow Sponsors and others to access formal ISNCSCI training through ASIA. Under Ms. Towle’s leadership, the team has developed processes, guidelines, policies, and training material that will be used to train staff, clinicians, and researchers involved in spinal cord injury clinical trials. The ASIA program will provide an opportunity for dissemination and training of international standards to the entire SCI community, including current and standardized material useful for both research and clinical practice.
James Hamer from DP Clinical is a member of the American Spinal Injury Association’s (ASIA) Autonomic Standards Committee. This Committee is responsible for overseeing the development of new standards documents related to spinal cord injury as well as continuous review and improvement of the existing ASIA documents on neurological and autonomic standards. The Committee is also responsible for the development of the online training program for ASIA standards and for the development and oversight of the International Data Sets project.
Michele Towle from DP Clinical has been a member of the ASIA Membership Committee since 2013. This Committee is responsible for recruiting and retaining individuals in the SCI community who have made a difference in the delivery of care for persons with SCI. The ASIA Membership Committee has expanded its role to cultivate relationships and communication in the allied health and scientific community in an effort to harness the concept of “bench to bedside” management of SCI. Also, in an effort to bring new members up to speed, a “mentorship for new members program” was initiated to facilitate early engagement in the learning and leadership opportunities ASIA has to offer. This committee serves both the best practitioners of today and those that will define the best evidenced-based practices of tomorrow.
Michele Towle, Assistant Director, Spinal Cord Injury Program, at DP Clinical has been elected to the Board of Directors for Unite 2 Fight Paralysis (U2FP) and will serve a three-year term. U2FP was founded in 2005 by three women living with paralysis as either spinal cord injury survivors or family members. U2FP is committed to the achievement of cures for paralysis through education, advocacy, and support for scientific research.
DP Clinical Assistant Director, Spinal Cord Injury Program, to Participate in NINDS SCI Common Data Elements Oversight Committee
Michele Towle, Assistant Director, Spinal Cord Injury Program, at DP Clinical has accepted an invitation to participate in the National Institute of Neurological Disorders and Stroke (NINDS) Spinal Cord Injury Common Data Elements Oversight Committee. The purpose of the Committee is to annually review SCI common data elements based on recommended updates and feedback and also to make recommendations regarding suggested corrections and updates.
NINDS conducts spinal cord research in its laboratories at the National Institutes of Health (NIH) and also supports additional research through grants to major research institutions across the country. Advances in research are giving doctors and patients hope that repairing injured spinal cords is a reachable goal. Advances in basic research are also being matched by progress in clinical research, especially in understanding the kinds of physical rehabilitation that work best to restore function.
Come meet the DP Clinical team at the following conferences: